...
首页> 外文期刊>BMJ: British medical journal >Managing retinal vein occlusion
【24h】

Managing retinal vein occlusion

机译:视网膜静脉阻塞管理

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Retinal vein occlusion-obstruction of the retinal venous system by thrombus formation, external compression, or disease of the vein wall-is the second most common retinal vascular disease after diabetic retinopathy.2 Pooled data from population studies in the United States, Europe, Asia, and Australia suggest that about 16 million adults are affected by this condition.3 Not all cases need treatment, In the past, the visual prognosis for most patients was poor because treatment comprised lowering the pressure in the eye, if raised, and laser treatment to try to control associated complications. However, two new treatments have recently been licensed in the US and the European Union, one of which has been approved by the National Institute for Health and Clinical Excellence (NICE) for use in England and Wales. Consequently, the outlook for patients with retinal vein occlusion is likely to improve. We review the diagnosis and management of retinal vein occlusion and examine the evidence for the effectiveness of the newly licensed drugs.
机译:视网膜静脉occlusion-obstruction视网膜静脉系统血栓形成、外部压缩,静脉壁或疾病第二个最常见的视网膜血管疾病糖尿病retinopathy.2人口研究在美国,欧洲,亚洲和澳大利亚建议约1600万成年人是受此影响condition.3情况下需要治疗,在过去,视觉大多数的病人的预后很差,因为治疗包括降低压力眼,如果提高了,而激光治疗尝试控制相关的并发症。新疗法最近的许可美国和欧盟,其中一个国家健康研究所和批准临床机构(NICE)在英格兰和使用威尔士。与视网膜静脉阻塞可能改善。我们检查视网膜的诊断和管理静脉阻塞并检查的证据新注册的药物的有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号